Arkolith/Insider Trading/KIN/Form 4

Chin Richard

Chief Executive Officer, DirectorKindred Biosciences, Inc. (KIN) · full profile →Form 4 · filed Aug 30, 2021
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
14
5 non-derivative · 9 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 27, 2021Disposed to issuer(D)2K$9.25$19K0
Aug 27, 2021Disposed to issuer(D)2K$9.25$19K0
Aug 27, 2021Disposed to issuer(D)2K$9.25$19K0
Aug 27, 2021Disposed to issuer(D)2K$9.25$19K0
Aug 27, 2021Disposed to issuer(D)1.7M$9.25$15.8M0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 27, 2021Disposed to issuer(D)198K$2.79$552K0
Aug 27, 2021Disposed to issuer(D)198K$5.80$1.1M0
Aug 27, 2021Disposed to issuer(D)175K$2.85$499K0
Aug 27, 2021Disposed to issuer(D)350K—$00
Aug 27, 2021Disposed to issuer(D)400K—$00
Aug 27, 2021Disposed to issuer(D)300K—$00
Aug 27, 2021Disposed to issuer(D)394K$4.81$1.9M0
Aug 27, 2021Disposed to issuer(D)400K$8.89$3.6M0
Aug 27, 2021Disposed to issuer(D)175K$0.50$88K0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001250853-21-000092) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML